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Uroporphyrinogen III Synthase Knock-In Mice Have the Human
Congenital Erythropoietic Porphyria Phenotype, Including the
Characteristic Light-Induced Cutaneous Lesions
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Congenital erythropoietic porphyria (CEP), an autosomal recessive inborn error, results from the deﬁcient but not
absent activity of uroporphyrinogen III synthase (URO-synthase), the fourth enzyme in the heme biosynthetic
pathway. The major clinical manifestations include severe anemia, erythrodontia, and disﬁguring cutaneous in-
volvement due to the accumulation of phototoxic porphyrin I isomers. Murine models of CEP could facilitate
studies of disease pathogenesis and the evaluation of therapeutic endeavors. However, URO-synthase null mice
were early embryonic lethals. Therefore, knock-in mice were generated with three missense mutations, C73R, V99A,
and V99L, which had in vitro–expressed activities of 0.24%, 5.9%, and 14.8% of expressed wild-type activity,
respectively. Homozygous mice for all three mutations were fetal lethals, except for mice homozygous for a spon-
taneous recombinant allele, V99AT/V99AT, a head-to-tail concatemer of three V99A targeting constructs. Although
V99AT/V99AT and C73R/V99AT mice had ∼2% hepatic URO-synthase activity and normal hepatic microsomal
heme and hemoprotein levels, they had 20% and 13% of wild-type activity in erythrocytes, respectively, which
indicates that sufﬁcient erythroid URO-synthase was present for fetal development and survival. Both murine
genotypes showed marked porphyrin I isomer accumulation in erythrocytes, bone, tissues, and excreta and had
ﬂuorescent erythrodontia, hemolytic anemia with reticulocytosis and extramedullary erythropoiesis, and, notably,
the characteristic light-induced cutaneous involvement. These mice provide insight into why CEP is an erythroid
porphyria, and they should facilitate studies of the disease pathogenesis and therapeutic endeavors for CEP.
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Congenital erythropoietic porphyria (CEP [MIM
263700]), also known as “Gu¨nther disease,” is an au-
tosomal recessive inborn error of heme biosynthesis due
to the low but not absent activity of uroporphyrinogen
III synthase (URO-synthase [EC 4.2.1.75]) (Romeo and
Levin 1969; Anderson et al. 2001). This enzyme cata-
lyzes the cyclization and isomerization of the linear te-
trapyrrole hydroxymethylbilane (HMB; aka “preuro-
porphyrinogen”) to uroporphyrinogen III (Burton et al.
1979; Jordan et al. 1979; Battersby et al. 1980). In the
absence of URO-synthase activity, HMB rapidly cyclizes
nonenzymatically to the nonphysiologic uroporphyri-
nogen I isomer (Burton et al. 1979), which is metabo-
lized to coproporphyrinogen I. Uroporphyrinogen I and
coproporphyrinogen I are oxidized to their respective
porphyrin I isomers: uroporphyrin (URO) I and copro-
porphyrin (COPRO) I. Thus, the deﬁcient UROS activ-
ity in CEP results in incomplete metabolism of HMB
and an accumulation of the pathologically toxic URO
and COPRO I isomers.
The human URO-synthase gene, located on chro-
mosome 10q26.2, has alternative housekeeping and er-
ythroid-speciﬁc promoters whose mRNAs both encode
the 265-aa, 29-kDa monomeric enzyme (Aizencang et
al. 2000a, 2000b). To date, 135 URO-synthase muta-
tions have been identiﬁed in patients with CEP (Human
Gene Mutation Database) (Stenson et al. 2003), includ-
ing 22 missense mutations whose mutant enzymes have
varying amounts of residual activity (see, e.g., Desnick
and Astrin 2002). In fact, the presence and severity of
clinical manifestations in CEP depend on the amount of
residual URO-synthase activity and range from non-
immune hydrops fetalis to a milder, later-onset formwith
only cutaneous photosensitivity and compensated he-
molysis (Anderson et al. 2001; Desnick and Astrin
2002). Thus, phenotype-genotype correlations have
been established for certain URO-synthase mutations
(reviewed by Desnick and Astrin [2002]).
The major manifestations of CEP include hemolytic
anemia and cutaneous photosensitivity (Anderson et al.
2001; Desnick and Astrin 2002; Bickers and Frank
2003). Anemia due to erythrocyte hemolysis can be life-
threatening if the marrow cannot compensate, and
severely affected patients are transfusion dependent.
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Splenomegaly and splenic sequestration may cause pan-
cytopenia (Anderson et al. 2001). Other manifestations
include erythrodontia and bone loss (Piomelli et al.
1986; Fritsch et al. 1997; Anderson et al. 2001). He-
molysis releases the toxic porphyrin I isomers into the
circulation, with subsequent deposition in the skin,
bone, other tissues, feces, and urine. Exposure to sun-
light and other UV sources results in cutaneous photo-
sensitivity, manifested by blistering of the epidermis in
sun-exposed areas. The subepidermal bullae and vesicles
are prone to rupture, and secondary infection leads to
cutaneous scarring and deformities, including loss of
digits, eyelids, nostrils, and ears. Corneal scarring can
lead to blindness. Hypertrichosis of the face and ex-
tremities is common (Poh-Fitzpatrick 1986), and exten-
sive pigment changes, including hyperpigmentation and
depigmentation, occur in minimally exposed areas. The
skin and corneal damage presumably results from the
phototoxic excitation of the accumulated URO and CO-
PRO I isomers, producing singlet oxygen with subse-
quent lipid peroxidation and membrane damage follow-
ing exposure to sunlight (Kaufman et al. 1967; Dawe et
al. 2002; Bickers and Frank 2003). However, the patho-
genic mechanism of the dermal photosensitivity has not
been investigated, primarily because of the lack of an
animal model of CEP.
For severely affected patients, bone marrow trans-
plantation (BMT) has been curative (Shaw et al. 2001;
Dupuis-Girod et al. 2005). However, BMT requires at
least a haploidentical match and is associated with a
signiﬁcant risk of morbidity and mortality. Thus, efforts
have been directed to develop stem-cell gene therapy for
CEP (e.g., Kauppinen et al. 1998; Mazurier et al. 2001;
Geronimi et al. 2003). Although the success of BMT has
provided the rationale for gene-replacement strategies,
the major obstacle to preclinical studies of the safety and
effectiveness of various therapeutic endeavors is the lack
of a CEP animal model.
A previous effort to develop a knockout mouse model
of human CEP was unsuccessful because URO-synthase
homozygous null mice were embryonic lethals at the 4–
8 cell stage (Bensidhoum et al. 1998), and heterozygotes
had no CEP phenotype. Therefore, on the basis of hu-
man mutant alleles, we selected murine URO-synthase
missense mutations that encoded a range of residual
activities (from ∼0.25% to 15% of in vitro–expressed
wild-type activity) to generate murine knock-in (KI)
models of CEP. Here, we report the generation of mice
heterozygous for the common severe C73R, milder
V99A, and synthetic V99L mutations. Mice homozy-
gous for these mutations were fetal lethals, with the ex-
ception of a fortuitous recombination event involving
triplication of the V99A targeting construct that resulted
in homozygous mice with !2% of wild-type activity in
liver but ∼20% of wild-type activity in erythrocytes.
V99AT/V99AT and C73R/V99AT mice had the charac-
teristic CEP biochemical and clinical phenotypes, in-
cluding systemic porphyrin accumulation, prominent
ﬂuorescent erythrodontia, ﬂuorescent peripheral eryth-
rocytes, and hemolytic anemia with reticulocytosis and
decreased haptoglobin levels (Bishop et al. 2004, 2005).
The V99AT/V99AT and C73R/V99AT genotypes were
transferred onto the hairless albino background (SKH1
strain) to facilitate studies of the skin photosensitivity.
After loading with 5-aminolevulinic acid (ALA) to ac-
celerate porphyrin accumulation, these mice developed
the typical light-induced cutaneous involvement and der-
matopathology. These mice provide viable murine mod-
els of CEP that should facilitate investigation of disease
pathogenesis and therapy.
Material and Methods
Cloning and Expression of Mutant Murine URO-Synthase
Alleles
The 798-bp murine wild-type cDNA coding sequence for
URO-synthase (GenBank accession number NM_009479) was
subcloned into the pKK223-3 vector (Amersham Biosciences)
at the EcoRI (5′) and XmaI (3′) restriction sites and was des-
ignated “pKK-WT.” Mutant constructs pKK-C73R, pKK-
V99A, and pKK-V99L were generated by site-directed muta-
genesis by use of the QuickChange method (Stratagene). To
avoid introduction of PCR-induced mutations in the vector,
each mutant construct was digested with BstXI andXhoI, after
which the 415-bp cassette carrying the respectivemutationwas
subcloned into the corresponding position in pKK-WT, the
sequence was conﬁrmed, and then each was used to transform
Escherichia coli DH5a competent cells (Invitrogen). After
growth in Luria broth cultures, induction, and cell lysis, the
supernatant URO-synthase enzymatic activity was measured
as described elsewhere (Tsai et al. 1987), except that the eryth-
rocyte lysate used to generate HMB-synthase was replaced by
5 units of homogeneous recombinant human HMB-synthase
(puriﬁed after expression in E. coli; 1 unit of enzyme activity
was equal to 1 nmol of HMB produced per h under the con-
ditions of the assay). For assays of URO-synthase in saline-
perfused mouse tissues, the HMB-synthase concentration was
increased to 10 units per assay. Protein concentrations were
measured using the Bradford protein assay (Bio-Rad).
Construction of the Targeting Vectors and Generation
of KI Mice
A genomic murine URO-synthase fragment was isolated
from mouse strain 129/OLA embryonic stem (ES) cells (Aizen-
cang et al. 2000b). The targeting replacement vectors con-
tained a 10.6-kb URO-synthase genomic fragment from intron
1 to intron 6 and had the C73R, V99A, or V99L mutation
introduced into exon 4 or 5, with adjacent, silent AvrII (for
exon 4 mutation) or HaeII (for exon 5 mutations) restriction
sites. A neomycin-resistance selection cassette (neo) was intro-
duced into intron 4 for positive selection with G418 (ﬁg. 1).
The primers used for vector construction and genotyping are
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Table 1
Primers Used for KI Vector Construction and Genotyping
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 1 Targeting of hypomorphic mutations into the murine URO-synthase gene by homologous recombination. A, Targeting vector.
The 11-kb URO-synthase gene sequence of the targeting construct in the pGEM-11Z vector contained a 2-kb ﬂoxed neo-selectable marker
cassette driven by the Rous sarcoma virus (RSV) promoter and four copies of the GTIIC-GTI enhancer cloned into the MfeI site of intron 4.
For the exon 4 C73R construct, the neo cassette was cloned in the reverse orientation. For the exon 5 V99A and V99L mutations, the neo
cassette was in the forward orientation. B, URO-synthase gene. The wild-type URO-synthase gene restriction map of the potential recombination
region is shown. C, Final targeted alleles. The targeted alleles showing the inserted mutations and marker gene in the reverse (corresponding
to the C73R allele) orientation are shown. The 1.5-kb EcoRI/XbaI external probe detects the 8.3-kb wild-type and 3.8-kb recombinant XbaI
restriction fragments for genotype analysis. For the other targeted alleles with the neo cassette in the forward orientation, the recombinantXbaI
fragment is 5.1 kb. D, Southern hybridization. Genomic DNA isolated from G418-selected ES cell clones was digested with XbaI and was
analyzed by Southern hybridization as described in the “Material and Methods” section. The exon 4 and 5 regions of the positive clones were
ampliﬁed, and the PCR products were sequenced, to conﬁrm the C73R mutation (lane 7), the V99L mutation (lane 2), and the V99A mutation
(lanes 4 and 5). The Std lane contains trace-labeled HindIII l marker DNA. Wtp wild type. E, Genotyping assay. Genomic DNA was ampliﬁed
with primer pairs U5 and U6 (table 1) and was digested with AvrII and HaeII for exons 4 and 5, respectively. For exon 4, the wild-type 249-
bp band was cut into 112- and 137-bp fragments, and, for exon 5, the 169-bp band was cut into 59- and 110-bp fragments. Hetp heterozygote;
Hz p homozygote; Nl p normal.
provided in table 1. Each targeting vector was sequence con-
ﬁrmed. Homologous recombination was performed in 129/Sv/
Ev/Tac ES cells, with all three constructs electroporated si-
multaneously; 1300 neo-selected clones were isolated, and
DNA was extracted and screened for correctly targeted re-
placements. One positive ES clone each was isolated for the
C73R and V99L mutations, and two positive clones were iden-
tiﬁed for the V99A mutation. After generation of chimeric
mice, PCR-based genotyping of offspring by ampliﬁcation of
exon 4 or 5 and restriction analysis of the AvrII site introduced
adjacent to the exon 4 mutation or the HaeII site introduced
adjacent to the exon 5 mutations were used to select founder
mice for each mutation (ﬁg. 1). Details of vector construction
and the generation and selection of ES clones and transgenic
mice are given in table 1 and appendix A. Chimeras weremated
with BL/6 mice, and germline mutant mice were mated with
wild-type or heterozygous littermates. The URO-synthase mu-
tations were also transferred onto the hairless albino SKH1
background.
Animal Studies
Blood was collected from the retro-orbital plexus in EDTA-
coated microhematocrit tubes (StatSpin) from animals under
open-drop isoﬂurane anesthesia, and tissues were harvested
after euthanization, were quick-frozen in liquid nitrogen, and
were stored at 95C. Hematologic indices were obtained us-
ing a Beckman-Coulter model LH-755 hematology analyzer.
Plasma haptoglobin levels were determined by a solid-phase
ELISA (Life Diagnostics). Feces and urine were collected in
metabolic cages every 24 h from individual mice. URO-syn-
thase enzymatic activity was measured in prokaryotic cell lys-
ates, as described above.
Porphyrin Quantiﬁcation
Porphyrin isomers in urine, feces, plasma, erythrocytes, liver,
and enzyme assays were analyzed by high-performance liquid
chromatography of the free-acid isomers, as described else-
where (Lim and Peters 1986; Lim et al. 1988; Kennedy and
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Table 2
Prokaryotic Expression of Murine and Human URO-Synthase
Missense Mutations
GENOTYPE
HUMANa MURINEb
Activity
(U/mg protein) %WTc
Activity
(U/mg protein) %WTc
Wild type 77.6 100 864  50 100
C73R !.8 !1.0 2.1  1.2 .24
V99A 4.3 5.6 51  16 5.9
V99L NAd NAd 128  54 14.8
a Human enzymatic activity in (expressed in prokaryotes) reported
by Xu et al. (1995) and Warner et al. (1992).
b Mean (SD) activity measured in bacterial lysates; see the “Ma-
terial and Methods” section for details.
c Percentage of wild-type activity levels.
d NA p not applicable. V99L has not been reported in human
patients with CEP.
James 1993), by use of a –mm BDS Hypersil column250# 4.6
(Thermo-Hypersil), with detection by a Waters Model 474
ﬂow ﬂuorometer (excitation wavelength 405 nm; emission
wavelength 618 nm; gain 100; attenuation 32). Porphyrins in
unﬁxed blood smears were visualized with an Olympus Model
BX61 motorized ﬂuorescence microscope ﬁtted with an oil-
immersion 100# UPLANFl objective, a Texas Red ﬂuores-
cence ﬁlter block, an Applied Imaging Model ER-3339 cooled
CCD camera, and the Applied Imaging Cytovision version 3.1
image-capture software.
Phenobarbital Treatment and Quantitation of Microsomal
Hemoproteins
Approximately 1-mo-old male mice were treated with 120
mg/kg phenobarbital intraperitoneally andwere sacriﬁcedwith
saline perfusion of tissues after 40 h. Livers were harvested
from wild-type and knockout mice after overnight starvation,
were minced, were homogenized in 0.15 M potassium phos-
phate buffer (pH 7.4; 5 ml/g liver), and were centrifuged at
12,000 g for 15 min. The supernatant was centrifuged at
105,000 g for 90 min. Microsomal pellets were washed twice
in the resuspension buffer, with centrifugation at 105,000 g
for 60 min, were resuspended in 50 mM potassium phosphate
buffer (pH 7.4; 20 mg protein/ml), were stored at 80C, and
were used within 3 mo (Janzen et al. 1994).
The determination of cytochrome P450 and cytochrome b5
concentrations was done by differential spectrophotometry in
accord with the method of Omura and Sato (1964). For cy-
tochrome b5, reduced nicotinamide adenine dinucleotide
(NADH) was used as reducing agent, and mM1 p 185424–409
cm1 for the reducedminus oxidized spectrum. For cytochrome
P450, sodium dithionite was used as reducing agent, and
mM1 cm1 for the reduced-CO minus reduced p 91450–490
spectrum. Protein concentration was determined using the Bio-
Rad DC Protein assay. The heme content was measured using
the pyridine hemochromogen method (Schenkman and Jans-
son 1998), with mM1 cm1 for the reduced p 32.4557–575
minus oxidized spectra.
Cutaneous Photosensitivity and Pathology
For the cutaneous photosensitivity studies only, the V99AT/
V99AT, C73R/V99AT, and wild-type mice were given 15 mM
ALA in their water ad lib for a 10-d period, to accelerate
porphyrin accumulation. Starting on day 2 of ALA treatment,
the SKH1 wild-type and mutant mice were exposed to four
GE F15T8-BLB–Black Light ﬂuorescent bulbs in two UVP
Model XX-15 bench lamps at a distance of 20 cm. The bulbs
ﬁltered out light above 420 nm, and a Plexiglas ﬁlter was added
that was selected to block UV light below 400 nm. Thus, most
of the light was from the mercury line emission at 405 nm,
the Soret absorbance wavelength responsible for porphyrin
ﬂuorescence. Exposures were for 12 h per d during the day-
time. The mice were sacriﬁced on day 18, skin was ﬁxed for
pathology, and all tissue samples were sectioned, stained with
hematoxylin and eosin and/or with periodic acid–Schiff (PAS),
mounted, and examined by light microscopy.
The thickness of folded skin in the shaved or hairless area
was measured after initiation of light exposure each day at
least three times, parallel to and near the backbone, with a
Fisherbrand Traceable digital calipers (Fisher Scientiﬁc). Dor-
sal skin from the mice was ﬁxed in neutral buffered formalin
overnight and was cut into multiple longitudinal strips and
prepared for histopathology in accordance with previously
published methods (Phelps et al. 1993).
Results
Generation of URO-Synthase KI Mice
Prokaryotic expression of the murine C73R andV99A
alleles resulted in 0.24% and 5.9%, respectively, of ex-
pressed wild-type activities, similar to the activities of
the corresponding human mutations (!1% and 5.6%),
whereas the expressed V99L mutation had 14.8% of
wild-type activity (table 2). Targeting vectors (see ﬁg. 1)
for each of the three hypomorphic alleles were mixed
together and were electroporated into ES cells. Recom-
binant clones for the three targeted alleles and a fourth
variant, a triplicated V99A targeted allele (designated
V99AT), were obtained from the single electroporation
procedure. Heterozygous founder mice were generated
for all three correctly targeted mutations plus the V99AT
variant. Segregation analysis revealed that all homozy-
gous mice were fetal lethals, except for the variant
V99AT line (table 3). Southern analyses of genomic
DNAs with the 3′-ﬂanking probe revealed the expected
fragments for all targeted lines, and sequence analysis
of both targeted exons 4 and 5 in each case conﬁrmed
the presence of both the mutations and adjacent silent
restriction sites (ﬁg. 1 and appendix A). However, South-
ern hybridization of the V99AT line with the neo probe
and sequencing of RT-PCR products from cellular RNA
(data not shown) revealed a head-to-tail concatemer of
three V99A targeting constructs that had inserted be-
tween exons 1 and 6 of the URO-synthase gene, as
shown schematically in ﬁgure 2. Remarkably, sequence
analysis showed that the third and most 3′ copy of exon
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Table 3
Segregation of KI Mutations
MATING
F1 OFFSPRING
x2 P CONCLUSION
No. of
Litters
Total
Offspring
No. of
/ Mice
No. of
/ Mice
No. of
/ Mice
WT/C73R # WT/C73R 20 148 64 84 0 58.1 !108 C73R/C73R p lethal
WT/V99A # WT/V99A 20 159 54 105 0 53.0 !108 V99A/V99A p lethal
WT/V99AT # WT/V99AT 3 27 4 15 8 1.52 .468 V99AT/V99AT p viable
WT/V99L # WT/V99L 20 168 53 115 0 56.3 !108 V99A/V99A p lethal
NOTE.—Chimeras generated from implantation of the selected ES cell clones were mated with wild-type (WT) BL/6, CD1, or SV129
mice, and the litters were genotyped as described in the “Material and Methods” section. For x2 analysis, the Chi-Square calculator (see
Web Resources) was used.
5 in the V99AT recombinant contained the insertedHaeII
restriction site but not the more 5′ V99A mutation pre-
sent in the other two copies (ﬁg. 2). RT-PCR studies
indicated barely detectable levels of the housekeeping
transcript, which is needed for viability, presumably the
result of splicing exon 1 to the last copy of exon 2B in
the concatemer (ﬁg. 2). The other abundant transcripts
containing exon 1 were alternatively spliced with trip-
licated exons 2–5, which would encode truncated en-
zyme polypeptides. In contrast, RT-PCR of the ery-
throid-speciﬁc transcript revealed a single wild-type
fragment length, indicating transcription by the ery-
throid promoter of the most 3′ copy in the V99AT con-
catemer, which had reverted to wild type (V99). Semi-
quantitative RT-PCR of total RNA from perfused
spleens indicated that expression of the housekeeping
and erythroid transcripts in the V99AT/V99AT mice was
∼3% and ∼30%, respectively, of expression in spleens
from wild-type mice. These levels were similar to the
housekeeping enzyme activity in liver and the combined
housekeeping and erythroid activities in spleen (table 4).
Of note, the V99AT allele expressed wild-type and not
mutant housekeeping or erythroid enzyme activities.
URO-Synthase Activities and Porphyrin Levels
in the V99AT/V99AT and C73R/V99AT Mice
The hepatic, splenic, and erythrocytic URO-synthase
activities in the V99AT/V99AT, C73R/V99AT, and wild-
type BL/6 mice are shown in table 4. The hepatic activ-
ities in the V99AT/V99AT and C73R/V99AT mice were
2.1% and 1.5% of wild-type, respectively, whereas the
erythrocytic activities were 20% and 13% of wild-type
and splenic activities were 44% and 32% of wild-type,
respectively. These ﬁndings were compatible with the
RT-PCR results that showed very low levels of house-
keeping transcripts but moderately abundant erythroid
transcripts. Splenic activities were markedly increased in
these mice and presumably reﬂect erythroid URO-syn-
thase activity from extramedullary erythropoiesis.When
these genotypes were transferred to the hairless albino
SKH1 background, hepatic, erythrocytic, and splenic
URO-synthase activities similar to those on the BL/6
background were observed (table 4).
Compared to wild-type concentrations, the total I
isomer (URO I plus COPRO I) concentrations in the
V99AT/V99AT and C73R/V99AT BL/6 mice were, re-
spectively, 2- and 25-fold greater in erythrocytes, 5- and
6-fold greater in plasma, 39- and 31-fold greater in
urine, and 62- and 108-fold greater in feces, with the
majority of fecal type I isomer being COPRO I (83%
and 94%, respectively), which is more soluble in bile
(table 5). Of note, URO I in the perfused livers of C73R/
V99AT BL/6 mice was elevated 60-fold from wild-type
levels, indicating a hepatic component of porphyrin I
accumulation. In contrast, the levels of the porphyrin III
isomers were maximally increased only 4- and 6-fold
above wild-type levels for V99AT/V99AT and C73R/
V99AT BL/6 mice, respectively (table 5), which indicates
that the deﬁcient URO-synthase activities stimulated
biosynthesis of HMB, presumably because of the in-
creased activity of ALA-synthase, the rate-determining
step of the pathway (Anderson et al. 2001). When the
V99AT/ V99AT and C73R/V99AT genotypes were trans-
ferred to the SKH1 background, similar I isomer in-
creases were observed in erythrocytes and plasma,
whereas the increase was more marked in urine and less
marked in feces (table 5). The life spans of the CEP mice
were not different from the wild-type life span of ∼2
years.
Bone, Tooth, and Erythroid Cell Fluorescence
V99AT/V99AT and heteroallelic C73R/V99AT, V99A/
V99AT, and V99L/V99AT mice were viable and had
marked porphyrin accumulation in bones, including
ﬂuorescent erythrodontia (ﬁg. 3A–3D), which is pa-
thognomonic for CEP and served as a diagnostic marker
for homozygous and heteroallelic mice. UV illumination
of newborn mice with a Wood’s lamp (Gupta and Singhi
2004) displayed the ﬂuorescent porphyrin-laden skele-
ton (ﬁg. 3A and 3B). The ﬂuorescence intensity of the
bones and teeth was inversely correlated with the resid-
ual URO-synthase activity; the C73R/V99AT mice had
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Figure 2 Diagram of the V99AT triplicated recombinant allele and major transcripts. Southern and sequence analyses of the PCR products
from reverse-transcribed and ampliﬁed liver mRNA from the homozygous V99AT mice revealed alternatively spliced transcripts and the presence
of at least three copies of exons 2B–5 inserted between exons 1 and 6 of the transgene. Other transcripts were identiﬁed with exon 5 present
or skipped in the ﬁrst and/or second repeats. The NotI site was used for linearization of the vector. PH and PE indicate the transcription start
sites directed by the housekeeping and erythroid promoters, respectively. The ampicillin-resistance gene (amp) was retained in two copies of
the concatemerized insert.
brighter bones and teeth than those of V99AT homo-
zygotes (not shown). Fluorescence microscopy of pe-
ripheral erythrocytes from these mice revealed occa-
sional highly ﬂuorescent cells (ﬁg. 3F), as is seen in
human patients with CEP.
Hematology
The hematologic indices for 16–18-mo-old wild-type/
wild-type, V99AT/V99AT, and C73R/V99AT BL/6 mice
were similar for erythrocyte counts, hematocrits, he-
moglobin concentrations, mean corpuscular hemoglo-
bin, mean corpuscular volume, and total leukocyte
counts (table 6). However, the reticulocyte counts in the
C73R/V99AT mice were markedly increased (33% vs.
8% in wild-type mice), and erythrocyte hemolysis was
evidenced by the 10-fold decrease in plasma haptoglobin
(1.2 ng/ml vs. 10.4 ng/ml in wild-type mice) (table 6).
The increased hemolysis, presumably caused by the in-
creased erythrocyte porphyrin I isomers, stimulated
erythropoiesis, as evidenced by the reticulocytosis and
higher splenic URO-synthase activity (table 4), which is
consistent with a compensated hemolytic anemia. Sple-
nomegaly in the C73R/V99AT mice was variable, with
splenic weights ranging from normal to ﬁve times normal
(based on percentage of total body weight). Although
the marrow appeared morphologically normal in wild-
type and C73R/V99AT mice, variably increased eryth-
ropoiesis and increased iron deposits were evident in
C73R/V99AT spleens.
Heme Content of Hepatic Microsomal Hemoproteins
To determine whether the 98% reduction of URO-
synthase activity in the liver compromised hemoprotein
biosynthesis, phenobarbital, which induces both heme
synthesis and cytochrome P450, was administered to
wild-type and C73R/V99AT BL/6 mice to place an ad-
ditional demand on heme synthesis. In wild-type mice,
the P450 content was reduced 75% at 40 h after pheno-
barbital administration, whereas the reduction in C73R/
V99AT mice was only 43% (ﬁg. 4). For cytochrome b5,
the reduction was more modest: 36% and 15% for wild-
type and CEP mice, respectively (ﬁg. 4). Cytochromes
P450 and b5 accounted for ∼45% of the total micro-
somal heme in both wild-type and mutant mice. Inter-
estingly, the sum of the two microsomal cytochromes
and the total microsomal heme were 50% higher in
C73R/V99AT mice than in wild-type mice, indicating
that, contrary to heme synthesis being compromised, it
was elevated in the CEP mice. The reduction in micro-
somal heme after phenobarbital administration has been
reported previously in rats and is presumably a result of
secondary induction of heme oxygenase by increased
heme levels (Correia and Burk 1978; Sun et al. 2002).
Cutaneous Photosensitivity
To assess the effect of 405-nm light on the skin of
wild-type, V99AT/V99AT, and C73R/V99AT mice, the
mutant genotypes were transferred onto the hairless al-
bino SKH1 background, and 15 mM ALA was added
to the drinking water to accelerate porphyrin I isomer
accumulation, as described in the “Material and Meth-
ods” section. The plasma porphyrin I isomer concen-
trations immediately increased in all treated mice to 2–
3-fold higher than those in untreated mice, with an over-
all increase of I isomer concentrations in themutantmice
of 8–10-fold above wild-type levels (table 5). After ex-
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Table 4
URO-Synthase Activities in KI Mice
MICE AND
GENOTYPE
LIVER ERYTHROCYTES SPLEEN
Activity
(U/mg protein) %WTa
Activity
(U/mg protein) %WTa
Activity
(U/mg protein) %WTa
BL/6:
WT/WT 8.72  1.23 100 20.1  .2 100 7.40  2.40 100
V99AT/V99AT .18  .05 2.1 4.04  .56 20 3.25  1.14 44
C73R/V99AT .13  .02 1.5 2.69  .10 13 2.36  .34 32
SKH1:
WT/WT 10.3  1.7 100 15.0  4.9 100 14.9  4.7 100
V99AT/V99AT .40  .10 3.9 4.6  1.3 34 7.4  1.3 50
C73R/V99AT .22  .14 2.1 1.4  .2 9.3 1.8  .5 12
NOTE.—Data are mean (SD) for three adult mice (aged 2–4 mo, except for SKH1 spleens, which
are from mice aged 2–8 mo).
a Percentage of wild-type (WT) activity levels.
posure to 405-nm light for 10 d, bifold skin thickness
in the C73R/V99AT mice increased twofold (from a
mean of 0.6 mm to a mean of 1.3 mm; ), whereasnp 3
there was no skin thickening in the wild-type or V99AT/
V99AT mice. Histopathologic examination of the wild-
type skin showed no evidence of acute or chronic pho-
todamage, showing a normal-thickness epidermis (10
mm), and the dermis (367 mm) was free of any signiﬁcant
inﬁltrate or ﬁbrosis (ﬁg. 5A). Typical of hairless albino
mice, numerous small cysts (remnants of aborted hair
follicles) were present in the deeper dermis. Similarly, the
V99AT/V99AT mice showed slight thickening of the
epidermis (30 mm) (ﬁg. 5B and inset), whereas the der-
mis (290 mm) was not thickened, consistent with a very
mild porphyrin photosensitivity. In marked contrast, the
C73R/V99AT mice showed evidence of the characteristic
light-induced cutaneous pathology of human CEP (ﬁg.
5C–5F). As shown in ﬁg. 5C, both the epidermis and
adnexa showed considerable acanthosis (51 mm) with a
focally compact horn, whereas the thickened dermis
(480 mm) had a minimal mononuclear inﬁltrate extend-
ing almost to the panniculus carnosus (ﬁg. 5C). Figure
5D shows the classic cutaneous pathology of CEP: a
noninﬂammatory, subepidermal bulla with clear-cut sep-
aration of the neutrophil-coated full-thickness epidermal
roof from the dermal ﬂoor, containing rare ﬂattened
basal keratinocytes, which most likely represent re-
epithelization from adjacent rudimentary follicles (ﬁg.
5D). Compared to unaffected skin from wild-type mice
(ﬁg. 5E), ectatic capillaries were observed in the super-
ﬁcial dermis of a C73R/V99AT mouse beneath the bul-
lae, and there was a thickening of the walls when stained
with PAS (ﬁg. 5F).
Discussion
Studies of the pathophysiology of CEP and efforts to
evaluate therapeutic endeavors have been hindered by
the lack of an animal model. Previous efforts to generate
a knockout mouse model of CEP by gene targeting were
unsuccessful because URO-synthase activity is required
for embryonic viability (Bensidhoum et al. 1998). Sim-
ilarly, homozygous knockout mice for other heme bio-
synthetic enzymes have also been fetal lethals (Lindberg
et al. 1996; Phillips et al. 2001), emphasizing the essen-
tial role of heme for embryonic development. Here, we
report the successful generation of murine models of
human CEP. Although our original strategy was based
on introducing missense mutations with residual URO-
synthase activities varying from ∼0.25% to 15% of the
prokaryotically expressed murine wild-type activity (ta-
ble 2), none of the correctly targeted homozygous mice
were viable. Fortuitously, an aberrant triplicated V99A
targeting vector produced viable homozygous V99AT/
V99AT BL/6 mice that had URO-synthase activities of
∼2% and ∼20% of wild-type in liver and erythrocytes,
respectively (table 4). When bred with the C73R het-
erozygotes, the C73R/V99AT heteroallelic BL/6 mice
were more severely affected, having ∼50% lower hepatic
and erythrocytic URO-synthase activities (consistent with
the essentially null activity of the C73R allele), higher
levels of porphyrin accumulation (tables 4 and 5), lower
haptoglobin levels, higher reticulocyte counts, more
prominent erythrodontia, and variable splenomegaly.
It is notable that the V99AT/V99AT and C73R/V99AT
mice were viable with !2% of wild-type hepatic activity
but had as low as ∼13% of wild-type erythroid activity.
Assays of total hepatic microsomal heme and the major
hepatic hemoproteins showed that microsomal heme
and cytochromes P450 and b5 were maintained at es-
sentially normal or elevated levels relative to wild-type
when the mice were treated with phenobarbital (ﬁg. 4).
These ﬁndings suggest that low levels of hepatic URO-
synthase are compatible with the production of the ma-
jor hepatic hemoproteins, even though there was a 60-
fold increase in porphyrin I isomers in the liver. That
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Table 5
Porphyrin Isomer Levels in URO-Synthase BL/6 and SKH1 KI Mice
Mice, Tissue, and Genotype URO I
Total I
Isomersa
Fold Increase
over WTb URO III
Total III
Isomersa
Fold Increase
over WTb
BL/6:
Erythrocytes (nmol/liter):
WT/WT 1.2  .2 4.2  .6 1 11  1 13  1 1.0
V99AT/V99AT 4.2  .8 8.0  .8 2 13  1 14  1 1.1
C73R/V99AT 64.9  36.2 103  56 25 19  5 22  5 1.7
Plasma (nmol/liter):
WT/WT 8.8  1.6 9.6  1.6 1.0 .58  .36 6  2 1.0
V99AT/V99AT 25  4 47  15 4.9 3.24  .20 17  5 2.8
C73R/V99AT 30  10 61  17 6.4 2.08  .55 14  3 2.3
Post-ALA plasma (nmol/liter):
WT/WT 8.7  5.1 12  4 1.2c 7.4  9.6 17  14 2.8c
V99AT/V99AT 67  24 91  27 1.9c 18  8.6 33  29 1.9c
C73R/V99AT 91  30 123  42 2.0c 21  14 22  9 1.6c
Urine (nmol/24 h):
WT/WT .12  .01 .14  .01 1.0 .06  .00 .14  .05 1.0
V99AT/V99AT 3.3  .6 5.4  .7 39 .12  .02 .38  .06 2.8
C73R/V99AT 2.3  .9 4.4  1.1 31 .09  .04 .54  .13 4.0
Feces (nmol/24 h):
WT/WT .32  .06 .74  .15 1.0 .15  .02 1.2  .3 1.0
V99AT/V99AT 7.7  4.6 46  18 62 .56  .25 4.6  1.5 3.8
C73R/V99AT 4.9  1.0 80  25 108 .53  .10 7.3  1.8 6.1
Liver (nmol/24 h):
WT/WT 2.05  .73 2.05  .73 1.0 1.14  .33 1.14  .33 1.0
C73R/V99AT 123  53 125  54 61 2.75  .09 2.75  .09 2.4
SKH1:
Erythrocytes (nmol/liter):
WT/WT 3.3  4.0 3.9  4.2 1.0 .94  .55 1.7  1.2 1.0
V99AT/V99AT 29  14 33  12 8.5 5.0  .8 8.1  2.4 4.8
C73R/V99AT 73  36 91  45 23 6.2  1.3 11  1.0 6.5
Plasma (nmol/liter):
WT/WT 2.9  1.1 5.1  1.3 1.0 1.3  .7 3.5  1.5 1.0
V99AT/V99AT 12  5 31  7 6.1 2.1  .7 5.7  2.5 1.6
C73R/V99AT 17  2 43  6 8.4 2.2  .6 5.4  .8 1.5
Post-ALA plasma (nmol/liter):
WT/WT 7.0  6.3 9.2  7.3 1.8c 5.2  5.1 12  11 3.4c
V99AT/V99AT 66  84 94  124 3.0c 28  46 46  67 8.1c
C73R/V99AT 46  35 76  40 1.8c 32  26 46  29 8.5c
Urine (nmol/24 h):
WT/WT .02  .01 .04  .02 1.0 .02  .01 .16  .04 1.0
V99AT/V99AT 1.9  1.6 5.0  4.1 120 .08  .07 .82  1.05 5.1
C73R/V99AT 4.9  3.0 8.6  3.2 210 .28  .11 .53  .16 3.3
Feces (nmol/24 h):
WT/WT 2.2  1.1 3.8  2.2 1.0 .36  .27 2.9  1.8 1.0
V99AT/V99AT 44  27 94  60 25 3.4  2.2 8.7  4.6 3.0
C73R/V99AT 18  3 124  12 33 .52  .12 7.5  2.4 2.6
a Total I isomers p URO I  COPRO I; total III isomers p URO III  COPRO III. Values are the average of levels in three
mice aged 1–2 mo.
b Fold increase over the wild-type total isomers, except for post-ALA plasma, for which the isomer values are the average daily
amounts over the entire supplementation period and the fold increase is from mice before ALA loading.
c The variation in the porphyrin levels in post-ALA plasma is presumably a result of the varying consumption of water containing
15 mM ALA.
such low hepatic URO-synthase activity does not cause
the encephalopathy manifested by the acute porphyrias
may be explained by the fact that the normal activity of
murine URO-synthase is ∼50-fold greater than that of
HMB-synthase (Bishop and Desnick 1982), the enzy-
matic defect in acute intermittent porphyria. Thus, 2%
of wild-type activity in the liver appears to be sufﬁcient
to produce adequate levels of heme for the hepatic hemo-
proteins. In contrast, the levels of erythroid URO-syn-
thase activity in the KI mice (up to 13% of normal in
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Figure 3 Tooth, bone, and erythrocyte cell ﬂuorescence in C73R/V99AT mice. Newborn C73R/V99AT mice had easily visualized ery-
throdontia, seen using a Wood’s lamp, and their bones displayed marked porphyrin ﬂuorescence. Illumination was as described in the “Material
and Methods” section for cutaneous exposure, and images were captured at f 2.8 for 1 s and ISO 100 on a 3.2-megapixel digital camera with
a Wratten #4 ﬁlter. A, Euthanized C57BL/6 mice, aged 1–2 d, ventral view, with wild-type mouse at left and C73R/V99AT mouse at right. B,
Same mice as in panel A (wild-type at left, C73R/V99AT at right) but dorsal view after skin removal. C, Wild-type mouse at age 31 d. D,
C73R/V99AT mouse at age 41 d. E, Peripheral blood smear of a wild-type mouse, ﬁnal magniﬁcation # ∼500. F, Peripheral blood smear of a
C73R/V99AT mouse, ﬁnal magniﬁcation # ∼500.
erythrocytes; up to 32% of normal in spleen) (table 4)
were not sufﬁcient to prevent biochemical or clinical
pathology. The mice had a compensated hemolytic ane-
mia, as evidenced by their 10-fold reduced plasma hap-
toglobin levels and by their ∼4-fold elevated reticulocyte
counts, and increased splenic URO-synthase activity,
consistent with extramedullary hematopoiesis. These
ﬁndings indicate that sufﬁcient erythroid URO-synthase
activity is critical for normal hematopoiesis and, most
importantly, for murine fetal development, since the cor-
rectly targeted V99A homozygotes, which have 6% of
wild-type activity, were fetal lethals even after removal
of the neo cassette. Taken together, these ﬁndings pro-
vide the ﬁrst pathophysiologic explanation of why URO-
synthase deﬁciency does not result in a hepatic porphyria
with acute neurologic attacks but rather in an erythro-
poietic porphyria with cutaneous manifestations. More-
over, these mice provide a human disease model to in-
vestigate the effects of BMT on the erythroid and hepatic
contributions to disease pathogenesis, particularly be-
cause hepatic and erythroid porphyrin production may
increase after puberty (Guarini et al. 1994).
Phenotypically, the clinical severity in human CEP has
been shown to correlate with the amount of residual
URO-synthase activity encoded by the patient’s URO-
synthase mutations (Anderson et al. 2001; Desnick and
Astrin 2002). The most common and severest human
genotype that is variably viable, C73R/C73R, presents
as nonimmune hydrops fetalis, or, if surviving to deliv-
ery, the newborn has a transfusion-dependent anemia
and marked cutaneous photosensitivity. Moderately se-
vere genotypes may have a milder transfusion-dependent
or compensated hemolytic anemia and experience severe
cutaneous photosensitivity, whereas milder genotypes
may have only cutaneous photosensitivity. When ex-
posed to light, all patients develop the characteristic skin
lesions, which may be mild to severe, depending on the
level of residual URO-synthase activity and light ex-
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Figure 4 Effect of phenobarbital (PB) on microsomal heme. Iso-
lation and quantitation of total microsomal heme and of microsomal
cytochromes P450 and b5 are described in the “Material and Meth-
ods” section. The unblackened bars represent wild-type mice, and the
blackened bars represent C73R/V99AT mice.Mean values (above bars)
are for three mice, and the error bars show 1 SD.
Table 6
Compensated Hemolytic Anemia in CEP Mice
Genotype
RBC
(106 cells/ml)
HCT
(%)
Hb
(g/dl)
MCH
(pg)
MCV
(ﬂ)
RDW
(%)
WBC
(103 cells/ml)
Reticulocytesa
(%)
Haptoglobin
(ng/ml)
WT/WT 8.7  1.0 41  5 15  2 17  1 47  1 17  2 5.4  2.5 7.9  6.5 10.4  5.7
V99AT/V99AT 7.6  1.0 36  4 13  1 17  1 48  2 18  2 4.8  3.7 19  20 8.8  5.1
C73R/V99AT 8.5  1.4 37  6 14  2 16  1 43  1 21  3 3.0  1.6 33  11 1.2  .2
NOTE.—The mean age of the mice was 16  3 mo, and the results are the mean (SD) of ﬁve male mice, except for the haptoglobin
data, for which the mean age was 18  2 mo and the results are the mean (SD) of 4–6 mixed-sex mice. Hb p hemoglobin; HCTp
hematocrit; MCH p mean corpuscular hemoglobin; MCV p mean corpuscular volume; RBC p red blood cells; RDW p red cell
distribution width; WBC p white blood cells.
a For the two-tailed nonparametric Mann-Whitney Wilcoxon test based on the ranks, the mean percentage reticulocyte values for the
wild-type and C73R/V99AT mice were signiﬁcantly different, with .P ! .01
posure. These lesions can become infected and lead to
scarring and disﬁgurement due to skin and/or bone loss.
The phenotype of the V99AT/V99AT and C73R/
V99AT BL/6 or SKH1 mice most closely resembles that
of the moderately severe human phenotype. The mice
had marked URO I and COPRO I accumulation in
erythrocytes, plasma, urine, and feces (table 5); the pa-
thognomonic ﬂuorescent erythrodontia (ﬁg. 3); a ﬂuo-
rescent skeleton; a compensated hemolysis; and the
characteristic light-induced cutaneous manifestations.
Of note, the porphyrin III isomer levels were greater in
the CEP mice than in wild-type mice. This paradoxical
ﬁnding in the mice also occurs in human CEP and other
porphyrias. These CEP mice should allow investigation
into the underlying mechanism(s) responsible for this
poorly understood phenomenon.
Notably, histologic evaluation of the cutaneous lesions
in murine CEP showed that they closely mimicked those
in human CEP (Kaufman et al. 1967; Bhutani et al.
1974; Horiguchi et al. 1989), including the characteristic
(1) subepidermal bullae; (2) reduplication of the base-
ment membrane around dermal capillaries, as demon-
strated by PAS-positive staining; and (3) variable dermal
sclerosis. The subepidermal bullae of C73R/V99AT mice
were composed of the characteristic full-thickness epi-
dermis, with dermal papillae forming the ﬂoor of the
blister. As seen in human CEP, there was no epider-
mal necrosis or inﬂammatory inﬁltrate in the bulla cavity
and only a few inﬂammatory cells in the dermis (ﬁg. 5C
and 5D). The typical reduplication of the basement
membrane with thickened PAS-positive material was
seen in the prominent capillaries of the dermis—presum-
ably because of the repeated episodes of vascular injury
and repeated bullae formation (ﬁg. 5E and 5F). The
characteristic dermal sclerosis of human CEP resulting
from continued light-induced injury was also evident in
the CEP mice (ﬁg. 5C and 5D), from the superﬁcial
dermis to the panniculus carnosus. Of interest, because
hypertrichosis is a known late feature of CEP, there also
was massive adnexal hyperplasia (ﬁg. 5C). Consistent
with the blocking of UVA and UVB radiation, the CEP
mice did not show the dermatopathology of UV damage
(no areas of conﬂuent necrosis or individually apoptotic
keratinocytes). Thus, the ability to generate these lesions
by ALA supplementation and controlled illumination
should facilitate studies of the pathogenic mechanisms
underlying the formation of these lesions, as well as pro-
vide a mouse model for studies of their prevention and
treatment.
Recently, Ged et al. (2006) reported a viable homo-
zygous KI mouse model of CEP with the URO-synthase
P248Qmutation that had !1% of wild-type erythrocytic
activity. Their mice were also generated with SV/129 ES
cells, retained the neo cassette, and were bred onto the
BL/6 background. When expressed in vitro, the human
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Figure 5 Sections from exposed skin on the backs of SKH1 mice. Panels A–D were stained with hematoxylin and eosin, and panels E
and F with PAS. A and E, Wild-type mouse. B, V99AT/V99AT mouse. C, D, and F, C73R/V99AT mice. A–D, Magniﬁcation #10, with #20
insets. E and F, Magniﬁcation #40.
P248Q allele had ∼0.5% of wild-type activity (Fonta-
nellas et al. 1996), which was signiﬁcantly less than the
in vitro activities of the murine V99A or V99L alleles
(table 2). Why the homozygous P248Q mice survived
while the homozygous V99A and V99L mice with the
neo cassettes were lethal is not clear. It is notable that
when the neo cassette was ﬂoxed out, the V99L ho-
mozygotes were viable, whereas the C73R and V99A
homozygotes were not, suggesting an enzymatic sur-
vival-threshold effect, similar to that seen in human CEP.
Studies are underway to determine at what stage of
embryogenesis does lethality occur in the homozygous
C73R and V99A mice.
In summary, a viable mouse model of human CEP has
been generated by gene targeting with murine missense
mutations that encode low levels of URO-synthase ac-
tivity. The V99AT/V99AT and the more severely affected
C73R/V99AT BL/6 and SKH1 mice had biochemical and
clinical phenotypes that closely resemble those of pa-
tients with moderately severe CEP. These models will
enable detailed studies of the underlying mechanisms of
the hemolytic anemia and light-induced cutaneous man-
ifestations, particularly the proposed free-radical/singlet-
oxygen damage hypothesis (Bickers and Frank 2003).
In addition, these mice provide the models required for
evaluation of the safety and efﬁcacy of various ther-
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apeutic endeavors for CEP, including light-blocking
agents, BMT, lentiviral-mediated gene therapy, and
novel stem-cell approaches.
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Appendix A
Targeting-Vector Construction
The strategy for targeted homologous recombination
in ES cells is shown in ﬁgure 1. A 14-kb genomic clone
containing the entire murine URO-synthase gene was
isolated from a 129SV/OLA mouse genomic library
(Sau3AI partials) in the l-FIX II vector (Stratagene [cat-
alog number 946305]) as described elsewhere (Aizen-
cang et al. 2000b). For generation of the targeting se-
quence for KI vector construction, an 11-kb SalI/EcoRI
restriction fragment from this clone extending from 144
bases 3′ of URO-synthase exon 1 to 25 bases 5′ of exon
6 was subcloned into the pGEM11Z vector (Promega)
and was designated “pGU1.” The entire 11-kb sequence
was obtained by automated ﬂuorescent Sanger enzy-
matic sequencing and from data in the Celera Genomics
database. For this and all following constructs, all li-
gation junctions and synthetic regions were sequence
conﬁrmed. For introduction of the three different mis-
sense mutations in exons 4 and 5, a 4.5-kb BspEI-to-
EcoRI fragment was subcloned from pGU1 into the
Litmus-38 vector (New England Biolabs) and was
designated “pLU1.” Site-directed mutagenesis (Quick-
Change protocol [Stratagene]) was used to introduce the
selected point mutations, along with an additional mu-
tation in a nearby codon wobble position that did not
alter the amino acid sequence but created a restriction
site for use in ES clone screening. Table 1 lists the mu-
tagenesis primers and the respective mutations intro-
duced in the two exons. For the C73R mutation and
adjacent AvrII site in exon 4, an internal sequence-con-
ﬁrmed 600-bp NsiI/BmgBI fragment with the desired
base changes was removed and ligated into the NsiI/
BmgBI–digested original pLU1 construct to generate
clone pLU2. For the two exon 5 mutations, V99A and
V99L, and their adjacent silent HaeII sites, an internal
1,200-bp MscI/NheI fragment was removed and ligated
into the pLU1 construct to yield clones pLU3 and pLU4,
respectively. The pLU2, pLU3, and pLU4 clones were
each cut with BspEI and EcoRI and were ligated back
into BspEI/EcoRI–digested clone pGU1 to generate
constructs pGUC73R, pGUV99A, and pGUV99L,
respectively.
To introduce a removable neo-selection marker into
the unique MfeI site in URO-synthase intron 4, an adap-
ter was synthesized using the N1 primer pair (table 1)
and was subcloned into NsiI/SacI–digested pGEM9Zf
(Promega) to yield clone pG1. A neo insert and ﬂanking
LoxP sites from clone pFN1 (kindly provided by Dr.
Douglas Forrest, Mount Sinai) were removed with SpeI
and ligated into the adapter SpeI site of clone pG1 to
yield clone pGFN1. The EcoRI/SalI fragment of pGFN1,
internal to the LoxP sequences, was replaced with the
EcoRI/SalI fragment of a neo construct containing a
weakened promoter (kindly provided by Dr. Thomas
Lufkin, Mount Sinai) to generate clone pGFN2. The
MfeI insert of pGFN2 containing the ﬂoxed neo cistron
was then subcloned into the unique MfeI site in intron
4 of plasmids pGUC73R, pGUV99A, and pGUV99L,
to generate constructs pGUC73Rneo, pGUV99Aneo, and
pGUV99Lneo, respectively. Plasmid pGUC73Rneo con-
tained the neo MfeI cassette in the reverse orientation,
whereas, in the other constructs, the cassette was in the
forward orientation.
Homologous Recombination in ES Cells
and Generation of Germline Chimeras
ES cell line TC1 (derived from strain SV129/SvEvTac
[Deng et al. 1995; Leder et al. 1997]) was electroporated
using a mixture of all three KI constructs linearized with
NotI, each at a concentration of 1 mg/ml. Three-hundred
ES cell clones were selected in G418. Genomic DNA
was isolated from ∼300 G418-resistant clones, and 10-
mg aliquots were digested with XbaI and then genotyped
by Southern hybridization to a 32P-radiolabeled (by
Rediprime II DNA Labeling System [Amersham Phar-
macia Biotech]), 1.2-kb external probe between the
EcoRI and XbaI sites immediately ﬂanking exon 6. The
external probe was obtained from SV129 DNA by PCR
using primer pair U7 (table 1). Positive clones were se-
quence conﬁrmed for the presence of the speciﬁc mu-
tations by ampliﬁcation and sequencing of exon 4 or 5
(by use of oligonucleotide primer pairs U5 and U6 in
table 1) and then were microinjected into C57BL/6 blas-
tocysts and implanted into C57BL/6 pseudo-pregnant
foster mothers. The exon 4 KI chimeric males were bred
with C57BL/6 females to generate F1 mice, whereas the
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F1 generation from the exon 5 KI chimeric males were
from out-bred CD1 females. Subsequent generations
have been maintained on this mixed C57BL/6–CD1
background.
Genotyping of KI Mouse DNA
Genomic DNAwas isolated from toe clips or tail snips
as described elsewhere (Laird et al. 1991), with minor
modiﬁcations. The tissue was diced with a scalpel and
was digested overnight with Proteinase K at 55C in an
Eppendorf Model 5436 Thermomixer shaker (at 1,300
rpm [Brinkmann]). After centrifugation for 15 min at
10,000 g, the supernatant was mixed with an equal vol-
ume of isopropanol by inversion, and the precipitatewas
isolated as described (Laird et al. 1991) and was washed
once in 70% ethanol, followed by rehydration for 1.5
h at 65C with shaking at 1,300 rpm in the Thermo-
mixer. The exon 4 (249 bp) and exon 5 (169 bp) am-
plicons generated with primer pairs U4 and U5 (table
4) were digested withAvrII andHaeII, respectively.Only
the mutated amplicons were cleaved; the heterozygous
exon 4 amplicon yielded the expected 112- and 137-bp
AvrII fragments, and the heterozygous exon 5 amplicon
yielded the predicted 59- and 110-bp HaeII fragments
(data not shown). The fragments were visualized by elec-
trophoresis in 3% MetaPhor agarose gels (Cambrex Bio
Science).
Web Resources
The accession number and URLs for data presented herein are as
follows:
Chi-Square calculator, http://www.unc.edu/˜preacher/chisq/chisq.htm
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for URO-synthase
cDNA [accession number NM_009479])
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm
.nih.gov/Omim/ (for CEP)
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